Global pharma major Lupin Limited on Wednesday announced the launch of the first generic version of Oracea (Doxycycline Capsules, 40 mg), in the United States. The launch comes after getting approval from the United States Food and Drug Administration (U.S. FDA).
Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. It is a broad spectrum antibiotic of the tetracycline class used in the treatment of infections caused by bacteria and certain parasites.
It is indicated to treat bacterial pneumonia, acne, chlamydia infections, Lyme disease, cholera, typhus, and syphilis. It is also prescribed to prevent malaria.
Doxycycline Capsules had estimated annual sales of $128 million in the U.S. (IQVIA MAT February 2024).
